The promiscuous receptor

BJU International

Volumn 104, Issue 9, 2009, Pages 1204-1207

  Newsom Davis, Thomas E ^a   Kenny, Laura M ^a   Ngan, Sarah ^a   King, Judith ^b   Waxman, Jonathan ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Cancer; Prostate; PSA; Response; Vitamin D

Indexed keywords

ANDROGEN RECEPTOR; CALCIUM; ERGOCALCIFEROL; PROSTATE SPECIFIC ANTIGEN; VITAMIN D;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CALCIUM BLOOD LEVEL; CANCER GROWTH; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG WITHDRAWAL; GLEASON SCORE; HUMAN; LEG PAIN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DIETARY SUPPLEMENTS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; VITAMIN D; VITAMINS;

EID: 70349970408     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08599.x     Document Type: Article

References (28)

1. Grino PB, Griffin JE, Wilson JD. Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology 1990 126 : 1165 1172
2. Tata JR. Signalling through nuclear receptors. Nat Rev Mol Cell Biol 2002 3 : 702 710
3. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993 149 : 607 609
4. Small EJ, Carroll PR. Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 1994 43 : 408 410
5. Suzuki H, Akakura K, Komiya A, Aida S, Akimoto S, Shimazaki J. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 1996 29 : 153 158
6. Hara T, Miyazaki J, Araki H et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003 63 : 149 153
7. Beer TM, Ryan CW, Venner PM et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 2007 25 : 669 674
8. Kaeding J, Belanger J, Caron P, Verreault M, Belanger A, Barbier O. Calcitrol (1alpha,25-dihydroxyvitamin D3) inhibits androgen glucuronidation in prostate cancer cells. Mol Cancer Ther 2008 7 : 380 390 (Pubitemid 351302531)
9. Krishnan AV, Moreno J, Nonn L et al. Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. J Steroid Biochem Mol Biol 2007 103 : 694 702
10. Huang YC, Hung WC. 1,25-dihydroxyvitamin D3 transcriptionally represses p45Skp2 expression via the Sp1 sites in human prostate cancer cells. J Cell Physiol 2006 209 : 363 369
11. Beer TM, Garzotto M, Park B et al. Effect of calcitriol on prostate-specific antigen in vitro and in humans. Clin Cancer Res 2006 12 : 2812 2816
12. Swamy N, Chen TC, Peleg S et al. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2) -Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells. Clin Cancer Res 2004 10 : 8018 8027
13. Bao BY, Hu YC, Ting HJ, Lee YF. Androgen signaling is required for the vitamin d-mediated growth inhibition in human prostate cancer cells. Oncogene 2004 23 : 3350 3360
14. Qiao S, Pennanen P, Nazarova N, Lou YR, Tuohimaa P. Inhibition of fatty acid synthase expression by 1alpha,25-dihydroxyvitamin D3 in prostate cancer cells. J Steroid Biochem Mol Biol 2003 85 : 1 8
15. Ting HJ, Bao BY, Reeder JE, Messing EM, Lee YF. Increased expression of corepressors in aggressive androgen-independent prostate cancer cells results in loss of 1alpha,25-dihydroxyvitamin D3 responsiveness. Mol Cancer Res 2007 5 : 967 980
16. Golovko O, Nazarova N, Tuohimaa P. Vitamin d-induced up-regulation of tumour necrosis factor alpha (TNF-alpha) in prostate cancer cells. Life Sci 2005 77 : 562 577
17. Crescioli C, Maggi M, Luconi M et al. Vitamin D3 analogue inhibits keratinocyte growth factor signaling and induces apoptosis in human prostate cancer cells. Prostate 2002 50 : 15 26
18. Beer TM, Myrthue A, Garzotto M et al. Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2004 13 : 2225 2232
19. Faupel-Badger JM, Diaw L, Albanes D, Virtamo J, Woodson K, Tangrea JA. Lack of association between serum levels of 25-hydroxyvitamin D and the subsequent risk of prostate cancer in Finnish men. Cancer Epidemiol Biomarkers Prev 2007 16 : 2784 2786
20. Park SY, Murphy SP, Wilkens LR, Stram DO, Henderson BE, Kolonel LN. Calcium, vitamin D, and dairy product intake and prostate cancer risk: the Multiethnic Cohort Study. Am J Epidemiol 2007 166 : 1259 1269
21. Porojnicu A, Robsahm TE, Berg JP, Moan J. Season of diagnosis is a predictor of cancer survival. Sun-induced vitamin D may be involved: a possible role of sun-induced Vitamin D. J Steroid Biochem Mol Biol 2007 103 : 675 678
22. Ali MM, Vaidya V. Vitamin D and cancer. J Cancer Res Ther 2007 3 : 225 230
23. Trump DL, Potter DM, Muindi J, Brufsky A, Johnson CS. Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer 2006 106 (10 2136 2142
24. Morris MJ, Smaletz O, Solit D et al. High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma. Cancer 2004 100 : 1868 1875
25. Schwartz GG, Hall MC, Stindt D, Patton S, Lovato J, Torti FM. Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin Cancer Res 2005 11 : 8680 8685
26. Woo TC, Choo R, Jamieson M, Chander S, Vieth R. Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy. Nutr Cancer 2005 51 : 32 6
27. Beer TM, Lemmon D, Lowe BA, Henner WD. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer 2003 97 : 1217 1224
28. Gross C, Stamey T, Hancock S, Feldman D. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol 1998 159 : 2035 2039